Crescent

Full-Continuum Women's Health
Specialty Management

A business case for the first governance-grade platform spanning fertility, maternity, autoimmune, GI, Rx, and lab management under one clinical and financial operating model.

Confidential · May 2026 · v1.1

Executive Summary

Women's health specialty spend is growing faster than any other benefit category, and the management tools available to buyers are fragmented by condition. Fertility vendors sell fertility. Maternity vendors sell maternity. Autoimmune and GI conditions fall through entirely. The result is duplicated care coordination, unmanaged pharmacy spend, and preventable clinical failures that cost the system billions per year and cost women years of misdiagnosis.

Crescent is a full-continuum specialty management company. It governs the clinical and financial lifecycle from fertility treatment through obstetric care, high-risk maternity management, postpartum support, autoimmune conditions (which affect women at 4:1 ratios), GI/digestive disorders (routinely misdiagnosed in women), specialty Rx, labs, and care navigation. One contract. One data model. One accountability structure.

The financial model is straightforward. For a 100,000-life employer book, Crescent generates $8.4M in annual savings against a $1.50-$3.00 PMPM fee. That is a 2.3x-4.7x ROI for the buyer. Cash-flow positive by Year 2. Revenue trajectory reaches $125.4M by Year 5 with a defensible exit valuation of $500-625M.See Section 5

---

The Problem

Maternal Health Is a National Clinical Failure

The United States has a maternal mortality rate of 17.9 deaths per 100,000 live births, down from a peak of 32.9 during 2021 but still far above peer nations.1 Black women die at 3.2 times the rate of white women, a disparity that has widened, not narrowed.2 The CDC's Maternal Mortality Review Committees determined that 84% of these deaths were preventable.3

The C-section rate sits at 32.5%, a decade high and still climbing, more than double the WHO's recommended 10-15% threshold.4 Every unnecessary C-section adds surgical cost, extends recovery, increases complication risk, and drives downstream spend. The average NICU admission costs $71,000.5 NICU avoidance is the single largest financial lever in maternity management.

Autoimmune Conditions Are Systematically Underserved

80% of autoimmune patients are women.6 The average time to diagnosis is 4.6 years.7 During those years, patients cycle through specialists, accumulate imaging and lab costs, fill prescriptions that treat symptoms rather than causes, and deteriorate. Autoimmune flare management alone represents projected savings of $3.2M per 100,000 covered lives annually, based on flare reduction and biologic management modeling.

GI Misdiagnosis Is a Women's Health Problem

Total US GI spend reached $111.8B in 2024.8 Women have 41% more GI-related emergency department visits than men.9 IBS is the most common misdiagnosis for endometriosis patients, with diagnostic delays averaging 7-10 years.10 The misdiagnosis creates years of inappropriate treatment, repeated ED utilization, and delayed surgical intervention that would have resolved the underlying condition.

Care Fragmentation Makes All of It Worse

A woman managing fertility, pregnancy, a postpartum autoimmune flare, and GI symptoms will interact with four or five separate vendor programs if her employer or plan has them at all. More likely, she has one (fertility) and the rest is unmanaged fee-for-service. No single entity owns the longitudinal clinical picture. No one is governing Rx spend across conditions. No one is steering to high-performing providers. The fragmentation is the problem, and the market has not produced a solution because the market built condition-specific point solutions.

---

Market Opportunity

The governance-addressable portion of this market, B2B specialty management services, represents approximately $4-8B annually. Women's health startups raised $2.6B in 2024.12 McKinsey estimates that closing the women's health gap represents a $1 trillion global GDP opportunity.13 The capital and the attention are there. The architecture is not.

49 states plus DC now provide 12-month postpartum Medicaid coverage, up from a handful three years ago.14 This creates a structural tailwind. Every state that extends coverage creates a new population that needs managed, and Medicaid MCOs are the buyers.

Competitive Landscape

Maven is a telehealth front door. Progyny is a fertility carve-out. Pomelo is maternity outcomes. Lantern is surgical steering. None of them governs the full clinical and financial continuum. Nobody manages fertility and maternity and autoimmune and GI and Rx and labs as a single integrated specialty book. That is the white space.

---

The Product

Crescent is a specialty management company. It sits between the payer (or self-funded employer) and the delivery system, governing clinical pathways, provider performance, pharmacy utilization, and care transitions across the full women's health continuum. It is not a telehealth app. It is not a digital front door. It is an operating layer.

---

Financial Model

Unit Economics: 100,000-Life Employer Book

Crescent charges $1.50-$3.00 PMPM depending on module selection and population size. At the midpoint ($2.25 PMPM), the buyer's annual cost for a 100,000-life book is $2.7M against $8.4M in savings. That is a 3.1x ROI. At the floor fee, ROI reaches 4.7x. At the ceiling, 2.3x.

Sensitivity Analysis

Even the conservative scenario produces a positive ROI. The model does not require optimistic assumptions to work.

Revenue Trajectory

Pre-revenue model. Assumptions and derivation follow.

Cash-flow positive by Q3 of Year 2. The revenue ramp assumes three anchor clients in Year 1 (small-to-mid employer, one TPA, one regional plan pilot), expanding through referral and measured sales investment in Years 2-3.

Simplified P&L

Year 1: $1.1M revenue, ~$2.2M operating cost (clinical team, technology, overhead) = -$1.1M. Year 2: $8.2M revenue, ~$5.5M operating cost = +$2.7M (cash-flow positive Q3). Gross margins exceed 65% at scale as fixed costs are absorbed across growing member base.

---

Go-to-Market

Employers and TPAs (First Revenue: Months 4-12)

Self-funded employers between 10,000 and 100,000 lives are the fastest-closing buyers. They have benefits decision-makers who can move in one renewal cycle. They feel women's health cost pressure directly. They are already buying Progyny or Maven and know those tools only cover part of the problem.

TPAs are force multipliers. One TPA relationship opens 20-50 employer clients. Crescent operates as a carve-out management layer that sits alongside the TPA's existing claims infrastructure. No integration required. Data exchange via standard 837/835 files and eligibility feeds.

Regional Health Plans (Scale Revenue: Months 6-18)

Regional plans with 200,000 to 2,000,000 members are the scale buyers. Relationship-building begins at launch. Sales cycles run 6-12 months. Crescent enters through a pilot population (typically the plan's commercially insured book) and expands to Medicaid managed care after demonstrated results. Employer traction accelerates the close but does not gate the conversation.

Medicaid MCOs (Structural Revenue: Months 12-24)

49 states plus DC now offer 12-month postpartum Medicaid coverage.14 Medicaid MCOs need maternity management that works, and they need it now. Sales cycles are the longest (9-18 months), which means engagement starts the earliest. Advisory relationships and conference presence begin at Day 0. Formal proposals follow employer outcomes data. Crescent's maternity module is the entry point. Autoimmune and GI modules follow as the relationship matures. This is the largest addressable population and the most defensible long-term position.

Pricing Models

• PMPM fee: $1.50-$3.00 per member per month, all modules included. Simple. Predictable. Easy to model against savings.
• Shared savings: Crescent takes a percentage of documented savings above a baseline. Higher upside, longer measurement period. Best for plans with clean claims data and actuarial staff.
• Hybrid: Base PMPM + shared savings kicker above a threshold. Most common structure in specialty management.

---

Competitive Positioning

The distinction matters. Maven, Progyny, and Pomelo are consumer-facing platforms. They build apps. They acquire members. They deliver services. They are vendors.

Crescent is a governance layer. It does not deliver care. It governs how care is delivered, by whom, at what cost, and with what clinical accountability. It manages provider performance. It manages pharmacy spend. It manages transitions between care settings. It sits between the payer and the delivery system and enforces standards.

This is the same model that built the specialty management category in musculoskeletal, oncology, and cardiac care. It works because payers and employers do not need another app their members may or may not use. They need someone to manage the book.

Why Not Maven?

Maven is a $1.7B company with 28M covered lives and $268M in ARR.16 It is a virtual care and navigation platform. It does not manage autoimmune conditions, GI conditions, specialty pharmacy, or labs. It does not govern provider performance. It does not manage claims-level economics. Maven is a consumer product. Crescent is an operating system.

Why Not Progyny?

Progyny generated $1.29B in revenue in 2024.17 It is the gold standard in fertility benefits. It is also only fertility benefits. A buyer who uses Progyny still needs a separate maternity vendor, has no autoimmune management, no GI management, no cross-condition Rx governance. Crescent does not compete with Progyny on fertility. It subsumes the entire category Progyny lives in.

Why Not Pomelo?

Pomelo raised $92M at a $1.7B valuation to manage maternity outcomes.18 It does one thing well. Crescent manages maternity and everything else. The buyer consolidates three to four vendor contracts into one.

---

Team & Founder

Crescent was built by someone who manages specialty risk for a living. The founder holds a senior product role on the payer side, focused on specialty risk. The gap in women's health management was visible from the inside. It was visible because the tools that exist do not do what governance requires.

The founder has built and sold healthcare companies. Has operated at the intersection of product, actuarial, and clinical operations for over a decade. Has designed the clinical pathway models, provider performance frameworks, and financial governance structures that Crescent will deploy.

Crescent is part of the Corridor family, which includes Cadence (specialty governance), Curated (episode-based care management), Caliber (claims verification), Covenant (delegation oversight), and FORGE (product lifecycle methodology). Each company addresses a different failure mode in the managed care operating stack. Crescent addresses the failure mode in women's health.

The early team will be lean. Clinical operations lead, data engineering lead, and two senior navigators for the first three employer accounts. Growth follows revenue, not the other way around.

---

Capital & Returns

Bootstrap Path

Crescent is designed to bootstrap. The first three clients generate enough revenue to fund operations through cash-flow positive. The operating model is people and data, not hardware and clinical infrastructure. Gross margins exceed 65% at scale because the delivery system is external.

Capital Requirements (If Raised)

Valuation Trajectory

Specialty management companies trade at 4-5x revenue at growth stage. At $125.4M Year 5 revenue, that produces an exit valuation of $500-625M. Comparable exits include Accordant Health (acquired by CVS for specialty management assets) and Magellan Specialty Health including NIA (acquired by Evolent for approximately $800M). The category has a track record of producing acquirable, high-margin businesses.

Exit Scenarios

• Strategic acquisition by a national payer: The most likely exit. A major national health plan that wants to own women's health governance rather than rent it. Timeline: Year 4-6.
• Acquisition by a PBM or specialty pharmacy: Crescent's Rx management module makes it valuable to any entity trying to control specialty drug spend. Timeline: Year 3-5.
• Acquisition by an existing women's health company: Maven or a comparable platform that wants governance capability it cannot build organically. Timeline: Year 3-5.
• Continued operation as a standalone business: $125M+ revenue with 65%+ gross margins is a business worth running. Not everything needs an exit.

---

The Ask

Crescent is not raising capital today. It is looking for partners. Crescent offers a full-fee-at-risk guarantee: if documented savings do not exceed fees in Year 1, the fee is waived for Year 2.

The first three clients define the company. They set the clinical benchmarks, generate the outcomes data, and prove the economic model. In exchange, they get a founder-led engagement, pricing at the floor of the range, and a governance partner with real operational experience in the categories being managed.

What Crescent Needs

• One self-funded employer (25,000-100,000 lives) willing to pilot the full-continuum model starting Q3 2026.
• One TPA partner with an existing employer book that has expressed demand for women's health management.
• One regional health plan willing to run a 12-month pilot on a commercially insured population.

What Partners Get

• Floor-rate pricing ($1.50 PMPM, all modules) for the duration of the pilot.
• Direct access to the founder and clinical operations lead. Not a sales team. Not an account manager. The people who built the model.
• Quarterly actuarial reporting with intervention-level savings attribution.
• A contractual guarantee: if savings do not exceed fees in Year 1, the fee is waived for Year 2.

The gap is real. The market has valued the pieces at over $5B in aggregate (Maven + Progyny + Pomelo + Lantern combined). Nobody has built the whole. That is what Crescent is for.